Difference between revisions of "Part:BBa K4477011:Design"

(→‎Design Notes)
(→‎References)
Line 19: Line 19:
  
 
===References===
 
===References===
−
1. 10.1038/ncomms9072
+
1. 10.1038/ncomms9072 <br>
 +
2. https://www.clinicaltrials.gov/ct2/show/NCT04776629
 +
3. https://abcentra.com/resources/abcentra-announces-first-patients-dosed-with-orticumab-in-clinical-trial/
 +
4. https://abcentra.com/our-science/

Revision as of 09:49, 12 October 2022


Human/mouse anti-apoB(MDA) (anti-oxLDL) IgG - complete expression cassette


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal NheI site found at 826
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 1911
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal SapI.rc site found at 455


Design Notes

Amino acid sequences reverse transcribed and codon optimized for expression in E. coli B (the parent strain of SHuffle). Illegal restriction enzymes were removed via codon optimization.

For detailed annotations, see Team Virginia 2022's Benchling folder here: https://benchling.com/mrkhoury/f_/YR4zZSUb-virginia-igem-2022-dna-constructs/

Source

Orticumab light chain amino acid sequence acquired from IMGT: https://www.imgt.org/3Dstructure-DB/cgi/details.cgi?pdbcode=9635 Orticumab heavy chain amino acid sequence acquired from IMGT: https://www.imgt.org/3Dstructure-DB/cgi/details.cgi?pdbcode=9635 Mouse heavy chain amino acid sequence acquired from NCBI: Gene ID: 16017


References

1. 10.1038/ncomms9072
2. https://www.clinicaltrials.gov/ct2/show/NCT04776629 3. https://abcentra.com/resources/abcentra-announces-first-patients-dosed-with-orticumab-in-clinical-trial/ 4. https://abcentra.com/our-science/